PL401632A1 - Kompozycja farmaceutyczna zawierająca inhibitor ACE i bloker kanałów wapniowych, sposób jej wytwarzania i jednostka dawkowania zawierająca tę kompozycję - Google Patents

Kompozycja farmaceutyczna zawierająca inhibitor ACE i bloker kanałów wapniowych, sposób jej wytwarzania i jednostka dawkowania zawierająca tę kompozycję

Info

Publication number
PL401632A1
PL401632A1 PL401632A PL40163212A PL401632A1 PL 401632 A1 PL401632 A1 PL 401632A1 PL 401632 A PL401632 A PL 401632A PL 40163212 A PL40163212 A PL 40163212A PL 401632 A1 PL401632 A1 PL 401632A1
Authority
PL
Poland
Prior art keywords
composition
calcium channel
channel blocker
ace inhibitor
preparation
Prior art date
Application number
PL401632A
Other languages
English (en)
Other versions
PL227900B1 (pl
Inventor
Elżbieta Turczyn
Original Assignee
Adamed Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49724636&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL401632(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adamed Spółka Z Ograniczoną Odpowiedzialnością filed Critical Adamed Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL401632A priority Critical patent/PL227900B1/pl
Priority to AU2013346397A priority patent/AU2013346397B2/en
Priority to PT138018247T priority patent/PT2919815T/pt
Priority to ES13801824.7T priority patent/ES2650468T3/es
Priority to HUE13801824A priority patent/HUE035163T2/en
Priority to EA201590529A priority patent/EA027568B1/ru
Priority to BR112015010119A priority patent/BR112015010119A2/pt
Priority to PL13801824T priority patent/PL2919815T3/pl
Priority to SG11201503441XA priority patent/SG11201503441XA/en
Priority to RS20171233A priority patent/RS56664B1/sr
Priority to EP13801824.7A priority patent/EP2919815B1/en
Priority to PCT/IB2013/060069 priority patent/WO2014076632A1/en
Priority to MX2015006122A priority patent/MX353689B/es
Priority to UAA201505719A priority patent/UA114439C2/uk
Priority to MYPI2015001135A priority patent/MY170451A/en
Publication of PL401632A1 publication Critical patent/PL401632A1/pl
Priority to PH12015501036A priority patent/PH12015501036B1/en
Priority to ZA2015/04265A priority patent/ZA201504265B/en
Priority to HK16101893.8A priority patent/HK1213807A1/zh
Priority to HRP20171863TT priority patent/HRP20171863T1/hr
Publication of PL227900B1 publication Critical patent/PL227900B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Wynalazek dotyczy kompozycji farmaceutycznej stanowiące mieszaninę inhibitora ACE występującego w postaci proszku i blokera kanałów wapniowych w postaci granulatu, w której proszek i granulat zawierają jedną lub więcej substancji pomocniczych. Wynalazek obejmuje również sposób wytwarzania takiej kompozycji oraz jednostkowej postaci dawkowania zawierającej taką kompozycję.
PL401632A 2012-11-15 2012-11-15 Kompozycja farmaceutyczna zawierająca inhibitor ACE i bloker kanałów wapniowych, sposób jej wytwarzania i jednostka dawkowania zawierająca tę kompozycję PL227900B1 (pl)

Priority Applications (19)

Application Number Priority Date Filing Date Title
PL401632A PL227900B1 (pl) 2012-11-15 2012-11-15 Kompozycja farmaceutyczna zawierająca inhibitor ACE i bloker kanałów wapniowych, sposób jej wytwarzania i jednostka dawkowania zawierająca tę kompozycję
MYPI2015001135A MY170451A (en) 2012-11-15 2013-11-12 A pharmaceutical composition containing an ace inhibitor and a calcium channel blocker
SG11201503441XA SG11201503441XA (en) 2012-11-15 2013-11-12 A pharmaceutical composition containing an ace inhibitor and a calcium channel blocker
EP13801824.7A EP2919815B1 (en) 2012-11-15 2013-11-12 A pharmaceutical composition containing an ace inhibitor and a calcium channel blocker
ES13801824.7T ES2650468T3 (es) 2012-11-15 2013-11-12 Una composición farmacéutica que contiene un inhibidor de la ECA y un bloqueador de los canales de calcio
HUE13801824A HUE035163T2 (en) 2012-11-15 2013-11-12 A pharmaceutical composition comprising an ACE inhibitor and a calcium channel blocker
EA201590529A EA027568B1 (ru) 2012-11-15 2013-11-12 Фармацевтическая композиция, содержащая ингибитор апф и блокатор кальциевых каналов
BR112015010119A BR112015010119A2 (pt) 2012-11-15 2013-11-12 composição farmacêutica que contém um inibidor de ace e um bloqueador do canal de cálcio
PL13801824T PL2919815T3 (pl) 2012-11-15 2013-11-12 Kompozycja farmaceutyczna zawierająca inhibitor ace i bloker kanału wapniowego
AU2013346397A AU2013346397B2 (en) 2012-11-15 2013-11-12 A pharmaceutical composition containing an ace inhibitor and a calcium channel blocker
RS20171233A RS56664B1 (sr) 2012-11-15 2013-11-12 Farmaceutski sastav koji sadrži ace inhibitor i blokator kalcijumskih kanala
PT138018247T PT2919815T (pt) 2012-11-15 2013-11-12 Uma composição farmacêutica contendo um inibidor eca e um bloqueador de canais de cálcio
PCT/IB2013/060069 WO2014076632A1 (en) 2012-11-15 2013-11-12 A pharmaceutical composition containing an ace inhibitor and a calcium channel blocker
MX2015006122A MX353689B (es) 2012-11-15 2013-11-12 Composición farmacéutica que contiene un inhibidor de la enzima de conversión de angiotensina y un bloqueador del canal de calcio.
UAA201505719A UA114439C2 (uk) 2012-11-15 2013-11-12 Фармацевтична композиція, що містить інгібітор ace та блокатор кальцієвих каналів
PH12015501036A PH12015501036B1 (en) 2012-11-15 2015-05-08 A pharmaceutical composition containing an ace inhibitor and a calcium channel blocker
ZA2015/04265A ZA201504265B (en) 2012-11-15 2015-06-12 A pharmaceutical composition containing an ace inhibitor and a calcium channel blocker
HK16101893.8A HK1213807A1 (zh) 2012-11-15 2016-02-19 包含 抑制劑和鈣通道阻斷劑的藥物組合物
HRP20171863TT HRP20171863T1 (hr) 2012-11-15 2017-11-29 Farmaceutski pripravak koji sadržava ace inhibitor i blokator kalcijevih kanala

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL401632A PL227900B1 (pl) 2012-11-15 2012-11-15 Kompozycja farmaceutyczna zawierająca inhibitor ACE i bloker kanałów wapniowych, sposób jej wytwarzania i jednostka dawkowania zawierająca tę kompozycję

Publications (2)

Publication Number Publication Date
PL401632A1 true PL401632A1 (pl) 2014-05-26
PL227900B1 PL227900B1 (pl) 2018-01-31

Family

ID=49724636

Family Applications (2)

Application Number Title Priority Date Filing Date
PL401632A PL227900B1 (pl) 2012-11-15 2012-11-15 Kompozycja farmaceutyczna zawierająca inhibitor ACE i bloker kanałów wapniowych, sposób jej wytwarzania i jednostka dawkowania zawierająca tę kompozycję
PL13801824T PL2919815T3 (pl) 2012-11-15 2013-11-12 Kompozycja farmaceutyczna zawierająca inhibitor ace i bloker kanału wapniowego

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL13801824T PL2919815T3 (pl) 2012-11-15 2013-11-12 Kompozycja farmaceutyczna zawierająca inhibitor ace i bloker kanału wapniowego

Country Status (18)

Country Link
EP (1) EP2919815B1 (pl)
AU (1) AU2013346397B2 (pl)
BR (1) BR112015010119A2 (pl)
EA (1) EA027568B1 (pl)
ES (1) ES2650468T3 (pl)
HK (1) HK1213807A1 (pl)
HR (1) HRP20171863T1 (pl)
HU (1) HUE035163T2 (pl)
MX (1) MX353689B (pl)
MY (1) MY170451A (pl)
PH (1) PH12015501036B1 (pl)
PL (2) PL227900B1 (pl)
PT (1) PT2919815T (pl)
RS (1) RS56664B1 (pl)
SG (1) SG11201503441XA (pl)
UA (1) UA114439C2 (pl)
WO (1) WO2014076632A1 (pl)
ZA (1) ZA201504265B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3275432A1 (en) * 2016-07-25 2018-01-31 H e x a l Aktiengesellschaft Dosage form with ace inhibitor
WO2021162562A2 (en) * 2020-02-10 2021-08-19 Adamed Pharma S.A. Stable ramipril composition and fixed dose composition comprising thereof
GB2595203A (en) * 2020-03-03 2021-11-24 Alkaloid Ad Skopje Formulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
DE3739690A1 (de) 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
US5093129A (en) 1989-01-30 1992-03-03 E. R. Squibb & Sons, Inc. Method for treating addiction to a drug of abuse employing an ace inhibitor
BR0003282A (pt) 2000-07-14 2002-02-26 Libbs Farmaceutica Ltda Associação farmacêutica para tratamento da hipertenção arterial e prevenção de doenças cardiovasculares outras, como infarto do miocárdio, acidente vascular cerebral e insuficiências cardìaca e renal
CA2357982A1 (en) 2001-09-28 2003-03-28 Bernard Charles Sherman Solid compositions comprising ramipril
WO2003059388A1 (en) 2002-01-15 2003-07-24 Delta Hf. Formulations of quinapril and related ace inhibitors
US20030215526A1 (en) 2002-03-08 2003-11-20 Scott Stofik Stable formulations of angiotensin converting enzyme (ACE) inhibitors
US20050181055A1 (en) 2003-10-08 2005-08-18 Mathur Rajeev S. Pharmaceutical compositions of quinapril
EA011712B1 (ru) 2004-03-29 2009-04-28 Ле Лаборатуар Сервье Способ производства твёрдой фармацевтической композиции
HUP0401170A2 (en) * 2004-06-10 2006-09-28 Richter Gedeon Vegyeszet Pharmaceutical composition comprising amlodipine besilate and lisinopril dihydrate and process for
NZ561486A (en) * 2005-03-15 2011-03-31 Lupin Ltd Pharmaceutical compositions of amlodipine and benazepril
WO2007040511A1 (en) * 2005-09-28 2007-04-12 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
WO2007056442A1 (en) 2005-11-07 2007-05-18 King Pharmaceuticals Research & Development, Inc. Compositions of stabilized ramipril in combination with another active agent
WO2008065485A2 (en) 2006-10-19 2008-06-05 Torrent Pharmaceuticals Limited Stable pharmaceutical compositions of a calcium channel blocker and an ace inhibitor
MA34130B1 (fr) * 2010-02-24 2013-04-03 Sanofi Aventis Deutschland Formulations pharmaceutiques solides de ramipril et de bésylate d'amlodipine et leur préparation

Also Published As

Publication number Publication date
SG11201503441XA (en) 2015-05-28
MX353689B (es) 2018-01-23
EP2919815B1 (en) 2017-09-06
PH12015501036A1 (en) 2015-08-17
BR112015010119A2 (pt) 2017-07-11
RS56664B1 (sr) 2018-03-30
ES2650468T3 (es) 2018-01-18
HUE035163T2 (en) 2018-05-02
MY170451A (en) 2019-07-31
PL2919815T3 (pl) 2018-01-31
WO2014076632A1 (en) 2014-05-22
AU2013346397A1 (en) 2015-06-18
HK1213807A1 (zh) 2016-07-15
PH12015501036B1 (en) 2015-08-17
UA114439C2 (uk) 2017-06-12
AU2013346397B2 (en) 2017-09-14
ZA201504265B (en) 2017-11-29
HRP20171863T1 (hr) 2018-01-12
MX2015006122A (es) 2015-08-05
EA027568B1 (ru) 2017-08-31
EA201590529A1 (ru) 2015-09-30
PT2919815T (pt) 2017-12-11
EP2919815A1 (en) 2015-09-23
PL227900B1 (pl) 2018-01-31

Similar Documents

Publication Publication Date Title
MX2018001990A (es) Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac.
PH12016501122A1 (en) Delayed release compositions of linaclotide
MX2016013486A (es) Activadores de canales ionicos y metodos de uso.
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
SG194469A1 (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors
PH12018500446A1 (en) Pyridinone dicarboxamide for use as bromodomain inhibitors
MY160456A (en) Benzodiazepine bromodomain inhibitor
JO3148B1 (ar) مركب مثبط لإشارات مسار notch
EA201690159A1 (ru) Способы и композиции для лечения рака
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
IN2014DN10670A (pl)
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
MY166449A (en) Pharmaceutical composition of rosuvastatin calcium
MX362879B (es) Usos novedosos.
EA201590268A1 (ru) Ариллактамные ингибиторы киназы
EA201890364A1 (ru) СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
EA201171414A1 (ru) Ингибиторы белков семейства iap
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
PL401632A1 (pl) Kompozycja farmaceutyczna zawierająca inhibitor ACE i bloker kanałów wapniowych, sposób jej wytwarzania i jednostka dawkowania zawierająca tę kompozycję
IN2013MU03428A (pl)
IN2013CH05440A (pl)
MX2012014969A (es) Composiciones farmaceuticas estables de amlodipina con telmisartan.